High Free Cash Flow Stocks
INVA is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
INNOVIVA INC (INVA) Stock Price & Overview
NASDAQ:INVA • US45781M1018
Current stock price
23.31 USD
+0.29 (+1.26%)
Last:
The current stock price of INVA is 23.31 USD. Today INVA is up by 1.26%. In the past month the price increased by 4.49%. In the past year, price increased by 31.39%.
INVA Key Statistics
52-Week Range16.52 - 25.145
Current INVA stock price positioned within its 52-week range.
1-Month Range21.615 - 23.63
Current INVA stock price positioned within its 1-month range.
- Market Cap
- 1.727B
- P/E
- 7.64
- Fwd P/E
- 11.61
- EPS (TTM)
- 3.05
- Dividend Yield
- N/A
INVA Stock Performance
Today
+1.26%
1 Week
+1.59%
1 Month
+4.49%
3 Months
+17.57%
Longer-term
6 Months +32.68%
1 Year +31.39%
2 Years +52.35%
3 Years +96.25%
5 Years +101.05%
10 Years +86.55%
INVA Stock Chart
INVA Stock Screens
INVA currently appears in the following ChartMill screener lists.
Low P/E Stocks
INVA is currently part of our Low P/E Stocks screen, indicating it cheap while it also meets financial health criteria.
Value Stocks with Strong Balance Sheets
INVA is currently part of our value stocks with Strong Balance Sheets screen, indicating it cheap while meeting strict financial health and debt criteria.
INVA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to INVA. When comparing the yearly performance of all stocks, INVA is one of the better performing stocks in the market, outperforming 80.92% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
INVA Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to INVA. Both the health and profitability get an excellent rating, making INVA a very profitable company, without any liquidiy or solvency issues.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
INVA Earnings
On February 25, 2026 INVA reported an EPS of 1.94 and a revenue of 114.61M. The company beat EPS expectations (245.81% surprise) and beat revenue expectations (9.49% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$1.94
Revenue Reported114.613M
EPS Surprise 245.81%
Revenue Surprise 9.49%
INVA Forecast & Estimates
11 analysts have analysed INVA and the average price target is 33.86 USD. This implies a price increase of 45.28% is expected in the next year compared to the current price of 23.31.
For the next year, analysts expect an EPS growth of -34.18% and a revenue growth 10.03% for INVA
Analysts
Analysts81.82
Price Target33.86 (45.26%)
EPS Next Y-34.18%
Revenue Next Year10.03%
INVA Groups
Sector & Classification
INVA Financial Highlights
Over the last trailing twelve months INVA reported a non-GAAP Earnings per Share(EPS) of 3.05. The EPS increased by 1505.26% compared to the year before.
Income Statements
Revenue(TTM)411.33M
Net Income(TTM)271.17M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 65.92% | ||
| ROA | 16.58% | ||
| ROE | 23.12% | ||
| Debt/Equity | 0.22 |
Chartmill High Growth Momentum
EPS Q2Q%646.15%
Sales Q2Q%24.84%
EPS 1Y (TTM)1505.26%
Revenue 1Y (TTM)14.67%
INVA Ownership
Ownership
Inst Owners106.59%
Shares74.07M
Float73.30M
Ins Owners1.08%
Short Float %9.3%
Short Ratio8.55
INVA Latest News, Press Relases and Analysis
3 days ago - By: Chartmill
INVA Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.66 | 874.551B | ||
| JNJ | JOHNSON & JOHNSON | 20.53 | 580.403B | ||
| MRK | MERCK & CO. INC. | 22.84 | 298.788B | ||
| PFE | PFIZER INC | 9.11 | 158.307B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.17 | 120.824B | ||
| ZTS | ZOETIS INC | 16.52 | 49.921B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.05 | 27.297B | ||
| VTRS | VIATRIS INC | 5.29 | 15.44B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.61 | 11.345B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.682B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.421B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.091B | ||
| CORT | CORCEPT THERAPEUTICS INC | 49.99 | 4.345B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INVA
Company Profile
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 159 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The firm's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Company Info
IPO: 2004-10-05
INNOVIVA INC
1350 Old Bayshore Highway, Suite 400
Burlingame CALIFORNIA 94010 US
CEO: Pavel Raifeld
Employees: 159
Phone: 16502389600
INNOVIVA INC / INVA FAQ
Can you describe the business of INNOVIVA INC?
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 159 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The firm's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Can you provide the latest stock price for INNOVIVA INC?
The current stock price of INVA is 23.31 USD. The price increased by 1.26% in the last trading session.
What is the dividend status of INNOVIVA INC?
INVA does not pay a dividend.
What is the ChartMill rating of INNOVIVA INC stock?
INVA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What do analysts say about INNOVIVA INC (INVA) stock?
11 analysts have analysed INVA and the average price target is 33.86 USD. This implies a price increase of 45.28% is expected in the next year compared to the current price of 23.31.
Can you provide the growth outlook for INNOVIVA INC?
The Revenue of INNOVIVA INC (INVA) is expected to grow by 10.03% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.